Form 4: OnKure Therapeutics Director Acquires Stock Options
SEC Form 4
Director Andrew John Phillips acquires stock options in OnKure Therapeutics.
Summary
- On October 4, 2024, Andrew John Phillips, a director of OnKure Therapeutics, Inc., acquired stock options.
- The stock options grant the right to buy 15,300 shares of Class A Common Stock at an exercise price of $18.2.
- The options vest monthly, with 1/36th of the shares vesting on November 4, 2024, and each month thereafter, contingent upon continued service.
- The options expire on October 3, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to stock option grants, which is a common practice. The director's acquisition could be interpreted as a positive sign, but it's not a major event.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.
Stakeholder Impact
- The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 10/04/2024 | Date of stock option transaction |
| 11/04/2024 | First vesting date of the stock options |
| 10/03/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.